Ascentage Pharma Announces Inclusion of Lisaftoclax in China’s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that its two core assets are covered by China’s 2026 National Reimbursement Drug List (NRDL), providing more patients with greater access to innovative treatment options. Specifically:

  • Lisaftoclax has been included in the 2026 NRDL for the first time for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
  • Olverembatinib has successfully renewed its NRDL coverage through renegotiation for the treatment of (1) adult patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs); and (2) adult patients with CML-CP or accelerated phase (CML-AP) harboring the T315I mutation.

With these developments, all approved indications for both of Ascentage Pharma’s novel drugs are now covered by the NRDL. The updated NRDL will officially take effect on January 1, 2027.

Lisaftoclax is a novel, oral, Bcl-2 selective inhibitor independently developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and hence restoring the normal apoptosis process in cancer cells. Approved in China in July 2025, lisaftoclax became the first domestically developed, original Bcl-2 inhibitor to receive marketing approval in the country. Its inclusion in the updated NRDL is expected to significantly improve treatment accessibility for patients with CLL/SLL in China, enabling more patients to gain timely access to new treatment options.

Olverembatinib is a novel, oral, third-generation BCR-ABL inhibitor independently developed by Ascentage Pharma, with support from China’s National Major New Drug Innovation Program. It is jointly commercialized in China by Ascentage Pharma and Innovent Biologics. Approved in China in November 2021, olverembatinib became the first third-generation BCR-ABL inhibitor to receive marketing approval in the country. The successful renewal of its NRDL coverage will continue to benefit more patients with CML in China by further improving the affordability and accessibility of long-term treatment.

Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, commented: “The successful inclusion of lisaftoclax in the NRDL and the renewal of olverembatinib’s coverage mark that all approved indications of Ascentage Pharma’s two core assets are now covered by the NRDL. For patients, it means greater access to innovative treatment options; for the company, it provides a solid basis for commercialization and sustained innovation; and for the industry, it demonstrates that China’s national reimbursement system supports domestically developed innovative drugs and further recognizes their value, boosting confidence across the pharmaceutical industry to continuously advance original innovation.”

Olverembatinib and lisaftoclax are currently under investigation and have not yet been approved by the US FDA.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant and/or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Ascentage Pharma
[email protected]
+1 (301) 792-6286

astr partners
[email protected]
+1 (917) 653-5122



SW Investors Have Opportunity to Join Smurfit Westrock Plc Fraud Investigation with SBS Law

SW Investors Have Opportunity to Join Smurfit Westrock Plc Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Smurfit Westrock Plc (“Smurfit Westrock” or “the Company”) (NYSE: SW) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Smurfit Westrock reported its Q3 financial results on October 28, 2026. The Company revealed that it missed consensus estimates on both revenues and profit, blaming the shortfall on an “unprecedented wave” of inflation. Based on this news, shares of Smurfit Westrock fell by 5.2% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Mesoblast Showcased at ASX Premier Investor Day Event

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities Exchange (ASX) Investor Day in Melbourne at the session titled “Meet the CEO: Inside Australia’s Listed Companies.”

The presentation highlighted Mesoblast’s transformation into a commercial-stage biotechnology company, continued growth of Ryoncil® (remestemcel-L-rknd) and the opportunity to leverage the Company’s cellular therapy platform across multiple high-value indications.

Mesoblast also outlined its key value-creation priorities, including expansion of RYONCIL into adult acute graft-versus-host disease, advancement of rexlemestrocel-L for inflammatory chronic low back pain and cardiopulmonary indications of end-stage heart failure and pulmonary hypertension related to left ventricular function, and disciplined deployment of capital to support commercial growth and late-stage development programs.

The presentation will be available through the ASX Investor Day resources page and on Mesoblast’s investor website.

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

References / Footnotes

  1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGvHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:


Corporate Communications / Investors

Paul Hughes  
T: +61 3 9639 6036  
   

Media – Global

Media – Australia
Rubenstein BlueDot Media
Caroline Nelson Steve Dabkowski
T: +1 703 489 3037 T: +61 419 880 486
E: [email protected] E: [email protected]



GILT Investors Have Opportunity to Join Gilat Satellite Networks Ltd. Fraud Investigation with SBS Law

GILT Investors Have Opportunity to Join Gilat Satellite Networks Ltd. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilat Satellite Networks Ltd. (“Gilat” or “the Company”) (NASDAQ: GILT) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Gilat reported its Q3 2026 financial results on November 10, 2026. The Company reduced its revenue guidance for the full year, explaining that, “Coupled with changing customer delivery and installation schedules, new orders are delayed and revenues are shifted into 2027 despite our significant order backlog. In Peru, an agreement originally expected to be signed at the first half of 2026 was signed at the end of the third quarter, shifting the associated revenues into 2027… Competitive pressure, longer decision-making process and GEO and LEO launch delays, customer delivery changes and ongoing commercial negotiations have shifted revenue timing and have affected our revenue outlook.” Based on this news, shares of Gilat fell by 20.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

IHRT Investors Have Opportunity to Join iHeartMedia, Inc. Fraud Investigation with SBS Law

IHRT Investors Have Opportunity to Join iHeartMedia, Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of iHeartMedia, Inc. (“iHeartMedia” or “the Company”) (NASDAQ: IHRT) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. iHeartMedia reported its Q3 financial results on November 9, 2026. The Company revealed adjusted EBITDA that fell below its guidance. The Company blamed a shortfall in political advertising revenue and a shift towards programmatic advertising. Based on this news, shares of iHeartMedia fell by more than 65% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Shareholders who lost money in shares of Kinross Gold Corporation (NYSE: KGC) should contact Wolf Haldenstein

Lead Plaintiff Deadline January 5, 2027

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed on behalf of purchasers of securities of Kinross Gold Corporation (“Kinross” or the “Company”) between February 18, 2026 and September 23, 2026, both dates inclusive (the Class Period”).

Investors who purchased Kinross shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for January 5, 2027


PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION

Kinross is a Canadian gold mining company with regional offices and mining facilities in the United States and abroad. Notably, Kinross operates Round Mountain, an open-pit gold mine in Nye County, Nevada.

According to the filed complaint, Kinross projected 2026 attributable production of 2.0 million gold equivalent ounces and repeatedly assured investors that it was “[o]n track to meet annual guidance” and “remain[ed] solidly on track to produce 2 million ounces.”

As alleged, Defendants failed to disclose that Kinross did not have the necessary resources and was otherwise ill-equipped to achieve its projections.

On September 23, 2026, Kinross issued an “Operational and Return of Capital Update” mid-quarter. In the release, Kinross cut their full year 2026 and 2027 attributable production guidance to 1.84 million to 1.86 million gold equivalent ounces. Kinross attributed the cut, in significant part, to ore recovery challenges at Round Mountain. The company later disclosed these challenges were operational in nature and were likely due to the use of oversized tools and machinery in the mining process.

On this news, Kinross stock dropped $3.20 per share, or 11.5%, from a closing price of $27.62 per share on September 23, 2026, to $24.42 per share on September 24, 2026.


WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.


There is no cost or obligation to speak with an attorney.


Contact:

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Bank of America Corporation (NYSE: BAC) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

Nationally Recognized Firm Urges Bank of America Investors to Explore Class Action Representation

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) — Lead Plaintiff Deadline: December 15, 2026. Investors who purchased (NYSE: BAC) securities between August 1, 2025 and October 13, 2026 may be eligible to recover losses.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bank of America securities between August 1, 2025 and October 13, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/bank-of-america-corporation-bac-class_action_lawsuit.

Bank of America Case Details

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

  1. Systemic weaknesses in Bank of America’s Bank Secrecy Act and Anti-Money Laundering (“BSA/AML”) compliance program caused BAC to fail to properly monitor trillions of dollars in transactions and to miss, delay, or file inaccurate or incomplete suspicious activity reports involving billions of dollars in suspicious activity;
  2. Internal reports had documented BAC’s BSA/AML compliance deficiencies for years, yet BAC failed to adequately remediate these deficiencies following the 2024 Consent Order;
  3. Bank of America, N.A. (“BANA”) also had deficiencies in its sanctions compliance program and processed transactions that were subsequently identified as apparent violations of multiple sanctions programs;
  4. Addressing these compliance deficiencies required significant additional resources and exposed BAC to substantial regulatory penalties and costs; and
  5. As a result, Defendants’ statements regarding the scope of BAC’s compliance failures, its progress in addressing the deficiencies identified in the 2024 Consent Order, and the anticipated costs and penalties associated with these issues were materially false and/or misleading.

What’s Next for Bank of America Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/bank-of-america-corporation-bac-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Bank of America you have until December 15, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to Bank of America Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Bank of America Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.



Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16

– All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who have reached response assessment –

– All six patients who have reached response assessment achieved a RANO objective response as their best overall response, with five patients showing complete responses (83.3%), including a previously reported stable disease, and one patient with a partial response (16.7%) with a 58% decrease in tumor measurements –

– Primary endpoints of feasibility and safety: planned Alpha DaRT sources were successfully deployed in all eight patients treated to date (100%), with no unanticipated serious adverse events (SAEs) –

– Follow-up scans in several of the patients show asymptomatic radiation necrosis, a known effect of focal radiation in previously irradiated brain tissue; whether these findings suggest necrosis or tumor recurrence is expected to become clearer with additional follow-up over the coming months –

– No definitive local recurrence observed in any treated patient –

– According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months –

– Conference call with principal investigator and the Company to be held tomorrow, Monday, November 16, 2026, at 8:30am ET –

JERUSALEM, Nov. 15, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced updated interim results from its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent glioblastoma (GBM). The results, measured as of November 11, 2026, were presented in a poster titled “First-In-Human Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma: Interim Analysis (REGAIN)” at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), held November 12-15, 2026, in Philadelphia, by the study investigator team from The Ohio State University Comprehensive Cancer Center (OSUCCC – James). Eight patients have been treated in the trial to date, six of whom have reached response assessment.

Uzi Sofer, CEO of Alpha Tau, commented: “In May we shared the first three patients treated with Alpha DaRT in the brain. Six months later, we see how truly transformational Alpha DaRT could be for recurrent GBM. Eight patients have been treated, every procedure has gone as planned, and every one of those patients is alive. The trial thus far has exceeded our wildest expectations, particularly in such a difficult cancer. Glioblastoma is one of the most devastating diagnoses in oncology, and recurrence is virtually inevitable. We look forward to following these patients’ progress as their scans mature, and to continuing enrollment toward 20 patients, which we believe, based on initial discussions, may support market submission requirements for Alpha DaRT in patients with this disease.”

Primary endpoints: Feasibility and Safety

The primary endpoints of the REGAIN trial are feasibility and safety. Planned Alpha DaRT sources were successfully deployed in all eight patients treated to date (100%). No unanticipated SAEs have been observed to date. One grade 3 SAE, previously reported in May 2026, was a seizure with Todd’s paralysis (a temporary paralysis following a seizure) that occurred in a patient with a prior history of seizures; it required a 48-hour hospital stay and resolved with steroids. All patients recovered from any adverse events without residual procedure-related symptoms.

Survival

All eight treated patients were alive as of November 11, 2026. Among the six patients who have reached response assessment, the median follow-up from trial enrollment was 6.9 months (range 3.1 to 11.6 months), and median overall survival has not been reached. Three of these patients have now been followed for more than eight months from enrollment.

Tumor Response

The six evaluable patients have reached response assessment by MRI. Measured as best overall response and using RANO criteria, all six patients (100%) achieved an objective response: five patients (83.3%) achieved a complete response, with no measurable tumor remaining at the treated site, and one patient (16.7%) achieved a partial response, with a 58% decrease in tumor measurements. The first three patients, whose initial results the Company reported in May 2026 as two complete responses and one stable disease, have all now been assessed as confirmed complete responses, the third patient having converted from stable disease to complete response upon longer follow-up. The responses in the three most recently assessed patients were observed at their early assessments and remain subject to confirmation on subsequent scans. No definitive recurrence within the treated area has been reported in any patient as of the cutoff date. One patient, the first patient treated, developed tumor progression away from the treated area approximately nine months after treatment while remaining free of recurrence in the area treated, and has received additional therapy.

Follow-up imaging has shown necrosis or suspected necrosis in or around the treated area in four of the six patients who have reached response assessment, which is a known effect of focal radiation, particularly in brain tissue that has previously been irradiated. The necrosis observed to date has been asymptomatic, and none of these findings was a serious adverse event. In two of these patients, the most recent scans, approximately three months after treatment, also showed new or increased enhancement adjacent to or outside the treated area, and the investigators cannot yet determine whether these findings represent necrosis or tumor progression. These patients are being evaluated with additional imaging and, as needed, biopsy. The Company expects the picture to become clearer over the coming months as additional scans are obtained, and the recurrence data reported today may change as a result.

The patients were treated at OSUCCC – James in Columbus, Ohio, by a multidisciplinary team led by Principal Investigator and Radiation Oncologist Joshua D. Palmer, MD, Medical Physicist Michael Degnan, MS, DABR and Neurosurgeon J. Bradley Elder, MD, using a novel stereotactic delivery approach designed specifically by Alpha Tau for intracranial use, through minimally invasive burr-hole access without open craniotomy. The REGAIN trial is designed to enroll up to 20 patients, and enrollment and follow-up are ongoing.

Dr. Joshua Palmer, Principal Investigator and Radiation Oncologist at the OSUCCC – James, commented: “I am even more encouraged by this newer set of interim results from the REGAIN trial, because we are now beginning to see survival. In recurrent glioblastoma, every patient who reaches six, nine and twelve months makes the picture more compelling, and all of our patients are alive. We have seen responses in every patient who has reached assessment, and have seen no definitive tumor regrowth in the area we treated. We are excited to continue to follow along these patients’ treatment journeys and to treat additional patients in the coming months.”

Dr. Robert Den, Chief Medical Officer of Alpha Tau, added: “The primary endpoints of this trial are feasibility and safety, and on both the data are consistent across all eight patients: every treatment was done as planned, and there have been no unanticipated serious adverse events. The response and survival data are incredibly encouraging for such a difficult disease, and longer follow-up will continue to be of interest in understanding the durability of these responses as we continue to enroll the study.”

Conference Call on Monday, November 16, 2026 at 8:30am ET

Alpha Tau will host a conference call with management, together with Dr. Joshua Palmer, on November 16, 2026, at 8:30 am ET.

To access the call, please register at https://alpha-dart-rgbm-at-sno-26.open-exchange.net/. An archived webcast will be available on the Company’s website following the event.

About the REGAIN Study

The REGAIN study is a prospective, open-label, single arm interventional study designed to evaluate the feasibility and safety of Alpha DaRT for the potential treatment of recurrent glioblastoma. The clinical trial is expected to enroll up to 20 U.S. patients with recurrent glioblastoma not amenable to surgical resection who have undergone a prior course of central nervous system radiation. The primary objective of the study is to evaluate the feasibility and safety of the treatment, following the Company’s promising results from pre-clinical studies. Additional information about the trial can be found at https://www.clinicaltrials.gov/study/NCT06910306

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to primarily affect the tumor and to spare healthy tissue surrounding it. For intracranial use, Alpha DaRT sources are delivered via a specialized stereotactic delivery system that interfaces with standard real-time neuronavigation platforms, with the goal of precise, image-guided source placement through minimally invasive burr-hole access without requiring open craniotomy.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. Other than its marketing approval in Japan for unresectable locally advanced or locally recurrent head and neck cancer and in Israel for products intended to treat Squamous Cell Carcinoma (SCC) of the Skin and Oral Cavity, the Alpha DaRT treatment has not been approved for commercialization or for use outside of an approved clinical trial. In addition, any statements or information that refer to the Alpha DaRT treatment in glioblastoma patients, including the interim results described herein and their interpretation, the confirmation of responses and the evaluation of imaging findings on subsequent scans, the expected enrollment and conduct of the REGAIN trial, the potential benefits and associated risks, safety, feasibility and efficacy, durability of responses, future applications and uses, and other expectations, beliefs and plans, including with respect to clinical trials, regulatory approvals and studies, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on Form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.



Investor Relations Contact:

[email protected]

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Endava plc (NYSE: DAVA) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

Nationally Recognized Firm Urges Endava Investors to Explore Class Action Representation

Lead Plaintiff Deadline: November 30, 2026. Investors who purchased (NYSE: DAVA) securities between September 4, 2025 and September 21, 2026 may be eligible to recover losses.

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) — Attorney Advertising — This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Endava securities between September 4, 2025 and September 21, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/endava-plc-dava-class_action_lawsuit.

Endava Case Details

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

  1. the accounting treatment for certain customer and supplier agreements and related matters required additional review;
  2. as a result, the Company would delay the release of its fourth quarter and full year 2026 financial results;
  3. there was reason to doubt the effectiveness of the Company’s internal controls and procedures; and
  4. as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.



What’s Next for Endava Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/endava-plc-dava-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Endava you have until November 30, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to Endava Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Endava Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.



SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Coastal Financial Corporation (NASDAQ: CCB) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

Nationally Recognized Firm Urges Coastal Investors to Explore Class Action Representation

Lead Plaintiff Deadline: December 1, 2026. Investors who purchased (NASDAQ: CCB) securities between October 28, 2024 and July 29, 2026 may be eligible to recover losses.

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) — Attorney Advertising–This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Coastal securities between October 28, 2024 and July 29, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/coastal-financial-corporation-ccb-class_action_lawsuit.

Coastal Case Details

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

  1. the credit quality of a substantial CCBX partner loan portfolio had materially deteriorated;
  2. the affected portfolio consisted of approximately $500 million in loans and represented nearly 23% of all CCBX loans;
  3. the deterioration exposed Coastal to significant losses despite the purported credit protection provided by the partner’s indemnification agreement; and
  4. as a result, Defendants’ statements regarding Coastal’s business, operations, financial condition, and credit risk were materially false and/or misleading and/or lacked a reasonable basis.

What’s Next for Coastal Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/coastal-financial-corporation-ccb-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Coastal you have until December 1, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to Coastal Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Coastal Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.